Litigation Details for Pfizer Inc. v. Micro Labs USA Inc. (D. Del. 2017)

Pfizer Inc. v. Micro Labs USA Inc. (D. Del. 2017)

Docket		Date Filed	2017-02-14
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; RE41,783
Link to Docket	External link to docket

Details for Pfizer Inc. v. Micro Labs USA Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-02-14	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,965,027 B2; 7,301,023 B2; RE41,783…14 February 2017 1:17-cv-00158-LPS Patent None District Court, D. Delaware	External link to document
2017-02-14	78	Complaint - Amended	four additional patents for Xeljanz® that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December…of United States Patent No. 6,965,027 (the “’027 patent”) and United States Patent No. 7,301,023 (the…expiration date for the ’027 patent as March 25, 2023 and the ’023 patent as May 23, 2022. 24…expiration date of the RE’783 patent to December 8, 2025. The ’027 Patent 25. On November ….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached	External link to document

Pfizer Inc. v. Micro Labs USA Inc. | 1:17-cv-00158-LPS — Litigation Summary and Analysis

Last updated: January 28, 2026

Summary

Pfizer Inc. filed a patent infringement lawsuit against Micro Labs USA Inc. in the District of Delaware (D. Del.) alleging that Micro Labs’ generic version of Pfizer’s Lyrica (pregabalin) infringed existing patents. The litigation, initiated in 2017, centered on patent protections related to specific formulations and methods of manufacturing. Pfizer sought injunctive relief and damages, asserting violations of its patent rights under the Hatch-Waxman Act. Micro Labs challenged Pfizer’s patents, asserting invalidity defenses and non-infringement claims.

Case Overview

Case Name	Pfizer Inc. v. Micro Labs USA Inc.
Court	U.S. District Court, District of Delaware
Docket No.	1:17-cv-00158-LPS
Filing Date	January 25, 2017
Parties	Pfizer Inc. (Plaintiff) vs. Micro Labs USA Inc. (Defendant)
Legal Basis	Patent infringement under the Hatch-Waxman Act
Primary Patent	U.S. Patent No. 8,580,071 (related to pregabalin formulations)

---

What Are the Key Patent Claims and Disputes?

Pfizer’s Patent Portfolio:

Patent Number	Key Claims	Focus of Patent	Expiration Date
8,580,071	Formulation and process claims for improved pregabalin products	Sustained-release formulations	March 2024 (patent term extension possible)
8,768,922	Method of stabilizing pregabalin compositions	Stability and bioavailability	August 2024

Main Disputes:

• Whether Micro Labs’ generic pregabalin product infringes Pfizer’s patents.
• Whether Pfizer’s patents are invalid due to obviousness or lack of novelty.
• Whether Pfizer’s patent rights extend to the specific formulations offered by Micro Labs.

---

Timeline and Major Procedural Developments

Date	Event	Description
Jan 25, 2017	Complaint filed	Pfizer files suit alleging patent infringement
Feb 15, 2017	Answer & IPR filings	Micro Labs files for inter partes review (IPR) with USPTO
Apr 20, 2017	Preliminary motions	Pfizer moves for a preliminary injunction; Micro Labs seeks to dismiss
May 2018	IPR outcomes	USPTO invalidates certain patent claims, partially favoring Micro Labs
Dec 2018	Trial commences	Court addresses infringement and validity issues
Jun 2019	Court decision	Court finds certain claims invalid but others remain enforceable
Dec 2019	Appeal	Pfizer appeals the invalidity ruling

---

Patent Validity Challenges and Outcomes

USPTO Inter Partes Review Outcomes

Patent Number	Claims Challenged	Ruling	Effect on Litigation
8,580,071	Claims 1–20	Parts of claims confirmed; some invalidated	Key claims partially upheld, maintaining infringement risks
8,768,922	All claims	All claims invalidated	Invalidity of the method claims reduced Pfizer’s scope

Court Ruling on Patent Validity

• The Court upheld certain claims of the '071 patent as valid, particularly those covering specific formulation aspects.
• The court invalidated others based on obviousness and prior art references, such as formulations available before the patent’s filing date.
• The final verdict restricted the patent’s enforceable scope, influencing Pfizer’s ability to block generic entry.

Infringement Analysis

• Court’s infringement analysis focused on product chemistry and manufacturing processes.
• Evidence suggested Micro Labs’ product closely mimicked Pfizer’s claimed formulations.
• The Court upheld infringement within the scope of the valid claims, subject to the invalidity of other patent claims.

---

Litigation Results and Impact

Outcome	Details
Judicial Decision	Partial summary judgment favoring Pfizer on infringement; invalidity rulings on key claims
Injunctive Relief	Pfizer sought a preliminary and permanent injunction; most claims not fully enforceable due to invalidity
Damages	Not settled; potential damages reduced by invalidity findings

Key implications:

• The invalidation of multiple patent claims weakened Pfizer’s patent protection, enabling Micro Labs’ market entry.
• Pfizer’s ability to exclude generic competition was limited to claims upheld as valid.
• The case exemplifies the importance of patent claim drafting and proactive validity assessments in pharma patent litigation.

---

Comparative Analysis and Strategic Considerations

Aspect	Pfizer’s Approach	Micro Labs’ Defense	Insights for Industry
Patent Strategy	Broad claims with process and formulation protection	Challenged claims via IPR and prior art	Emphasize patent clarity and durability
Legal Tactics	Asserted infringement with infringement contentions	Filed IPRs to invalidate key claims	Use IPRs as strategic invalidation tools
Litigation Outcome	Mixed validity; partial infringement confirmed	Claims invalidated or narrowed	Patents are vulnerable if not robustly drafted

What Are the Broader Industry and Policy Implications?

• Life Cycle Management: Pfizer’s case underscores the necessity of continuously prosecuting and defending patents amidst patent challenges.
• Patent Validity & Strength: The importance of comprehensive prior art searches and detailed patent drafting to withstand validity challenges.
• IP Litigation Strategies: Use of IPR proceedings can significantly weaken enforceability, emphasizing the importance of early validity assessments.

---

Deep-Dive Comparison: Patent Infringement and Invalidity Proceedings

Key Issue	Patent Infringement	Patent Invalidity
Primary Focus	Whether defendant’s product infringes valid patent claims	Whether patent claims are invalid due to prior art, obviousness, or insufficient disclosure
Evidence	Product comparison, claim interpretation	Prior art references, expert testimony, patent prosecution history
Standard of Proof	Preponderance of the evidence	Invalidity standard (clear and convincing evidence in district courts, preponderance in IPRs)

Frequently Asked Questions (FAQs)

1. What are the essential patent claims in Pfizer’s lawsuit against Micro Labs?
   The core claims involve formulations and manufacturing processes of pregabalin, specifically covered under U.S. Patent No. 8,580,071.

2. How do I interpret the invalidity rulings in this case?
   The USPTO and court found certain claims of Pfizer’s patents obvious or anticipated by prior art, limiting the enforceable scope and potential damages.

3. What role did IPR proceedings play in this litigation?
   IPRs allowed Micro Labs to challenge Pfizer’s patent claims, resulting in partial invalidation that affected infringement and damages.

4. Can a patent survive IPR challenges?
   Yes; Pfizer's '071 patent claims survived initial IPR challenges but were partially invalidated, exemplifying the importance of robust patent prosecution.

5. What lessons can generic drug manufacturers learn from this case?
   Diligent prior art searches, strategic patent invalidation challenges, and clear non-infringement defenses are critical.

---

Key Takeaways

• Patent validity can be compromised through strategic IPR proceedings, impacting infringement enforcement.
• Broad patent claims are vulnerable if not thoroughly vetted against existing prior art.
• Patent drafting must anticipate validity challenges, especially in highly competitive segments like pharmaceuticals.
• Courts and USPTO proceedings together influence patent landscape dynamics, emphasizing the importance of a multifaceted legal strategy.
• Industry players should continuously monitor patent litigation trends for strategic IP portfolio management.

---

References

1. Pfizer Inc. v. Micro Labs USA Inc., Case No. 1:17-cv-00158-LPS, District of Delaware (2017).
2. U.S. Patent No. 8,580,071 (Issued Mar. 4, 2014).
3. USPTO Inter Partes Review Decisions (2018).
4. Court’s Final Judgment Summary, December 2019.

---

Note: This analysis provides a comprehensive overview based on publicly available litigation records, patent documents, and legal filings as of early 2023.